Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Multicenter, Randomized, Double Blind, Placebo Controlled, Ascending Dose Finding, Efficacy, Pharmacokinetic and Safety Study of BXCL501 In Agitation Associated With Dementia

NCT04251910 is registered in ClinicalTrials.gov with BioXcel Therapeutics Inc as lead sponsor.

NCT NCT04251910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04251910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Multicenter, Randomized, Double Blind, Placebo Controlled, Ascending Dose Finding, Efficacy, Pharmacokinetic and Safety Study of BXCL501 In Agitation Associated With Dementia
Lead sponsor
BioXcel Therapeutics Inc
Phase
Phase 1/2
Overall status
Completed
Start date
December 27, 2019
Completion date
January 24, 2022
Enrollment
100 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

agitation,psychomotor, dementia